Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Andres J. M. Ferreri
The activity of feasibility of the proposed program will be assessed in HIV+ patients with Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and supporting treatment and redu ce late sequels. Available combinations in this setting are really source demanding and toxic combinations showing high rates of septic complication and a treatment-related mortality of near 20%.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of Burkitt's lymphoma (WHO 2008)
